Bristol-Myers Squibb Company
Utility Patents
Last updated:
List of all Bristol-Myers Squibb Company patents 334 in total
| Status | Patent |
|---|---|
Grant | Utility: Inhibitors of indoleamine 2,3-dioxygenase and methods of their use Filling date: 6 Sep 2025 Issue date: 28 Apr 2020 |
Grant | Utility: Additive systems for use in protein PEGylation Filling date: 6 Sep 2025 Issue date: 14 Apr 2020 |
Grant | Utility: Hepatitis C virus inhibitors Filling date: 6 Sep 2025 Issue date: 14 Apr 2020 |
Grant | Utility: Heteroaryl substituted aminopyridine compounds Filling date: 6 Sep 2025 Issue date: 14 Apr 2020 |
Grant | Utility: Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN.alpha. responses Filling date: 6 Sep 2025 Issue date: 7 Apr 2020 |
Grant | Utility: Spiroheptane salicylamides and related compounds as inhibitors of rock Filling date: 6 Sep 2025 Issue date: 7 Apr 2020 |
Grant | Utility: Indole carboxamide compounds Filling date: 6 Sep 2025 Issue date: 31 Mar 2020 |
Grant | Utility: Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Filling date: 6 Sep 2025 Issue date: 31 Mar 2020 |
Grant | Utility: Glucokinase activators and methods of using same Filling date: 6 Sep 2025 Issue date: 31 Mar 2020 |
Grant | Utility: Fibronectin binding domains with reduced immunogenicity Filling date: 6 Sep 2025 Issue date: 31 Mar 2020 |
Grant | Utility: Therapeutic TREM-1 peptides Filling date: 6 Sep 2025 Issue date: 31 Mar 2020 |
Grant | Utility: 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors Filling date: 6 Sep 2025 Issue date: 24 Mar 2020 |
Grant | Utility: BSL2v2c2-Ig polypeptides Filling date: 6 Sep 2025 Issue date: 17 Mar 2020 |
Grant | Utility: 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists Filling date: 6 Sep 2025 Issue date: 17 Mar 2020 |
Grant | Utility: 1,3-dihydroxy-phenyl derivatives useful as immunomodulators Filling date: 6 Sep 2025 Issue date: 17 Mar 2020 |
Grant | Utility: Compositions for cell culture and methods of using the same Filling date: 6 Sep 2025 Issue date: 17 Mar 2020 |
Grant | Utility: Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Filling date: 6 Sep 2025 Issue date: 10 Mar 2020 |
Grant | Utility: Glypican-3-binding fibronectin based scaffold molecules Filling date: 6 Sep 2025 Issue date: 10 Mar 2020 |
Grant | Utility: Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Filling date: 6 Sep 2025 Issue date: 3 Mar 2020 |
Grant | Utility: Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists Filling date: 6 Sep 2025 Issue date: 3 Mar 2020 |
Grant | Utility: Macrocyclic inhibitors of myeloperoxidase Filling date: 6 Sep 2025 Issue date: 3 Mar 2020 |
Grant | Utility: Substituted benzofuran compounds for the treatment of hepatitis C Filling date: 6 Sep 2025 Issue date: 25 Feb 2020 |
Grant | Utility: Triazolones and tetrazolones as inhibitors of ROCK Filling date: 6 Sep 2025 Issue date: 18 Feb 2020 |
Grant | Utility: IP-10 antibodies and their uses Filling date: 6 Sep 2025 Issue date: 11 Feb 2020 |
Grant | Utility: Acyl sulfonamide NaV1.7 inhibitors Filling date: 6 Sep 2025 Issue date: 4 Feb 2020 |
Grant | Utility: Prodrugs of imidazotriazine compounds as CK2 inhibitors Filling date: 6 Sep 2025 Issue date: 4 Feb 2020 |
Grant | Utility: 4-azaindole compounds Filling date: 6 Sep 2025 Issue date: 28 Jan 2020 |
Grant | Utility: Heteroaryl substituted pyridyl compounds useful as kinase modulators Filling date: 6 Sep 2025 Issue date: 28 Jan 2020 |
Grant | Utility: Inhibitors of indoleamine 2,3-dioxygenase and methods of their use Filling date: 6 Sep 2025 Issue date: 28 Jan 2020 |
Grant | Utility: Biaryl kinase inhibitors Filling date: 6 Sep 2025 Issue date: 28 Jan 2020 |
Grant | Utility: Nucleic acids encoding antibody polypeptides that antagonize CD40 Filling date: 6 Sep 2025 Issue date: 28 Jan 2020 |
Grant | Utility: Method of treating cancer using immune checkpoint inhibitor Filling date: 6 Sep 2025 Issue date: 28 Jan 2020 |
Grant | Utility: Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors Filling date: 6 Sep 2025 Issue date: 21 Jan 2020 |
Grant | Utility: Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions Filling date: 6 Sep 2025 Issue date: 21 Jan 2020 |
Grant | Utility: Antibodies against TIM3 and uses thereof Filling date: 6 Sep 2025 Issue date: 14 Jan 2020 |
Grant | Utility: Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses Filling date: 6 Sep 2025 Issue date: 7 Jan 2020 |
Grant | Utility: Cyclic dinucleotides as anticancer agents Filling date: 6 Sep 2025 Issue date: 31 Dec 2019 |
Grant | Utility: Aryl substituted bicycle heteroaryl compounds Filling date: 6 Sep 2025 Issue date: 31 Dec 2019 |
Grant | Utility: Compositions comprising a combination of nivolumab and ipilimumab Filling date: 6 Sep 2025 Issue date: 24 Dec 2019 |
Grant | Utility: Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor Filling date: 6 Sep 2025 Issue date: 17 Dec 2019 |
Grant | Utility: 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists Filling date: 6 Sep 2025 Issue date: 17 Dec 2019 |
Grant | Utility: Substituted nitrogen containing compounds Filling date: 6 Sep 2025 Issue date: 10 Dec 2019 |
Grant | Utility: Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof Filling date: 6 Sep 2025 Issue date: 10 Dec 2019 |
Grant | Utility: Selective NR2B antagonists Filling date: 6 Sep 2025 Issue date: 10 Dec 2019 |
Grant | Utility: Anti-ICOS agonist antibodies and uses thereof Filling date: 6 Sep 2025 Issue date: 3 Dec 2019 |
Grant | Utility: Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor Filling date: 6 Sep 2025 Issue date: 3 Dec 2019 |
Grant | Utility: Hepatitis C virus inhibitors Filling date: 6 Sep 2025 Issue date: 3 Dec 2019 |
Grant | Utility: Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma Filling date: 6 Sep 2025 Issue date: 3 Dec 2019 |
Grant | Utility: Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor Filling date: 6 Sep 2025 Issue date: 26 Nov 2019 |
Grant | Utility: Macrocycles as factor XIa inhibitors Filling date: 6 Sep 2025 Issue date: 26 Nov 2019 |
Showing 250 to 300 of 334 patents.